LGND · Ligand Pharmaceuticals Inc · Documents
$322.75
+5.42 (+1.71%)
At close · Oct 30
Return incl. dividend (before tax)
Q3 2026 earnings call transcript
Market Cap
$6.43B
Shares
20.00M
Volume · Oct 30
344.37K
Avg daily vol (3M)
241.18K
The company's filings as submitted to the SEC's EDGAR system — 10-K, 10-Q, 8-K, proxy statements and more — listed most recent first.
| Type | AI summary | Filing Date | Period | Open |
|---|---|---|---|---|
| 8-K | — | 2020-08-03 | — | |
| 8-K | — | 2020-06-11 | 2020-06-10 | |
| 10-Q | — | 2020-05-08 | 2020-03-31 | |
| 8-K | — | 2020-05-06 | — | |
| DEF 14A | — | 2020-04-24 | — | |
| DEFA14A | — | 2020-04-24 | — | |
| 8-K | — | 2020-04-07 | 2020-04-06 | |
| 8-K | — | 2020-04-06 | — | |
| 8-K | — | 2020-04-02 | 2020-04-01 | |
| 10-K | — | 2020-02-27 | 2019-12-31 | |
| 8-K | — | 2020-02-11 | — | |
| 8-K | — | 2020-02-06 | — | |
| 8-K | — | 2020-01-10 | — |
Showing 151–163 of 163 filings
Key facts
CIK
886163
CUSIP
53220K504
13F (30d)
134 filings
125 filers
Visit website
Investor relations